Protein Kinase C in Cancer Signaling and Therapy

Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980’s with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due

Protein kinase C (PKC), a family of serine-threonine kinases, rocketed to the forefront of the cancer research field in the early 1980’s with its identification as an effector of phorbol esters, natural products with tumor promoting activity. Phorbol esters had long been of interest to the cancer research field due

The serine/threonine protein kinase C (PKC) family has been extensively studied over the last 35 years, yet fundamental questions regarding the regulation of its signaling and its dysregulation in disease remain unanswered. PKC is involved in a multitude of cellular processes and precise control of the amplitude of PKC signaling

Previous evidence in our laboratory demonstrated the ability of estrogen to regulate specifically the protein kinase C (PKC) $\delta$ isoform in the rat and rabbit corpus luteum. The purpose of this study was to evaluate estrogen's ability to regulate PKC, specifically the PKC $\delta$ isoform, in the estrogen responsive, MCF-7

Members of the protein kinase C (PKC) family of Ser/Thr kinases are encoded by nine distinct but closely related genes, which give rise to more than 12 different protein isoforms via a mechanism of alternative RNA splicing. Most PKC proteins are ubiquitously expressed and participate in a plethora of functions